Tragara Pharmaceuticals, Inc. (Tragara)

Oncology Corporate Profile

HQ Location

10955 Vista Sorrento Parkway, Suite 120
San Diego, CA 92130

Company Description

Tragara Pharmaceuticals, Inc. is a privately held pharmaceutical company focused on the clinical and commercial development of proprietary drugs for the treatment of various cancers. Tragara Pharmaceuticals is focusing its development efforts on three NCEs and 1 companion diagnostic: Capoxigem (apricoxib, TG01) for the treatment of solid tumors and inflammation-related disorders; TG02, a novel small molecule that blocks, within a narrow potency range, major signaling pathways involving JAK2, FLT3, ERK5 and key cell cycle and transcriptional regulatory cyclin-dependent kinases (CDKs), with excellent pharmacological and pharmaceutical properties, and the flexibility of oral administration. The kinase pathways modulated by TG02 drive disease progression and survival in hematologic malignancies and solid tumors; TG03, a combination product of Capoxigem and an EGFR-TKI; ProGEM, our proprietary diagnostic being developed as a companion to Capoxigem, designed to execute our personalized medicine strategy.


This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
TG02multiple tyrosine kinase inhibitorAcute Myelogenous Leukemia (AML)I
TG02multiple tyrosine kinase inhibitorChronic Lymphocytic Leukemia (CLL)I
TG02multiple tyrosine kinase inhibitorMultiple MyelomaI

View additional information on product candidates here »


Recent News Headlines

There are no news items to display